InvestorsObserver
×
News Home

Should You Buy Geron Corporation (GERN) Stock on Friday?

Friday, August 20, 2021 11:25 AM | InvestorsObserver Analysts

Mentioned in this article

Should You Buy Geron Corporation (GERN) Stock on Friday?

Overall market sentiment has been neutral on Geron Corporation (GERN) stock lately. GERN receives a Neutral rating from InvestorsObserver Stock Sentiment Indicator.

Sentiment Score - ,neutral
Geron Corporation has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on GERN!

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With GERN Stock Today?

Geron Corporation (GERN) stock is lower by -1.23% while the S&P 500 is up 0.54% as of 11:22 AM on Friday, Aug 20. GERN is down -$0.01 from the previous closing price of $1.22 on volume of 568,278 shares. Over the past year the S&P 500 has risen 31.25% while GERN is down -32.40%. GERN lost -$0.31 per share in the over the last 12 months. To screen for more stocks like Geron Corporation click here.

More About Geron Corporation

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's leading drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses global rights to this drug. Click Here to get the full Stock Report for Geron Corporation stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App